The current market for diabetes products is large and growing. Both monitoring and therapeutic products have an excellent market outlook. Diabetes markets have long had major areas of unmet need, and that has not changed during the past several decades. In fact, the number of diabetic patients, especially in the United States, will increase at an accelerating rate over the next 20 years. With the recognition of diabetes as a public health issue of increasing importance, greater pressure will be placed on the medical products industry to satisfy those needs.

So significant is the market opportunity that young companies—many small biopharmaceutical firms—are springing up to meet this challenge, dedicating their entire R&D efforts to diabetes alone. New technologies and drug classes for the treatment of diabetes are being developed, as are methods of diabetes prevention for at-risk populations. It is a market brimming with opportunities and seeing increasing competition for those opportunities.

In such a dynamic marketplace, an understanding of the players and the playing field is an absolute necessity for any company active in diabetes product development, manufacture, and marketing. This completely revised and re-researched edition of Kalorama’s popular 2002 report is intended to provide the pertinent information vital to the serious competitors in the diagnostic and therapeutic diabetes marketplace.

This study considers diagnostics and therapeutics for diabetes type 1 and type 2, as well as the therapeutic markets for several long-term complications of diabetes including hypertension, dyslipidemia, cardiovascular disease, and vascular disorders (retinopathic, neuropathic, renal, and podiatric). The study details the top seven world markets in terms of epidemiology, market potential, and clinical and business trends. In addition new technologies are reviewed and competitors are profiled. Major conclusions of the study are presented with strategic implications and recommendations.

For this edition, a completely new chapter on nutritional and herbal supplementation approaches to diabetes examines the market presence of these new alternative products and their impact on traditional markets.

Related Reports:

The Worldwide Market for In Vitro Diagnostic Tests, 7th Edition
Aug 1, 2010 - KLI2613362 - $5,995.00

[pre pub] Kalorama 2010 Ultra Diagnostics Research Bundle
Jul 1, 2010 - KLI2703738 - $9,995.00

The Global Market for Medical Devices
Mar 1, 2010 - KLI2592223 - $1,500.00

What's Next in Vaccines? HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016 Pipeline
Feb 1, 2010 - KLI2578515 - $4,200.00

Obesity, Weight Loss and Diet Management Markets (Pharmaceutical, Surgical and Dietary Approaches)
Dec 1, 2009 - KLI1646597 - $3,500.00

Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads
Nov 1, 2009 - KLI2403357 - $3,995.00

2009 Worldwide Diagnostics Market Research Bundle
Oct 1, 2009 - KLI2401913 - $5,995.00

In Vitro Diagnostics in a Recessionary Economy: IVD Market Forecasts, Analysis and Success Strategies
May 1, 2009 - KLI2155316 - $1,995.00

H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)
May 1, 2009 - KLI2241990 - $800.00

Pharmaceutical Markets in India
Apr 1, 2009 - KLI2155338 - $1,295.00